A new trading day began on Tuesday, with Pacira BioSciences Inc (NASDAQ: PCRX) stock price down -1.74% from the previous day of trading, before settling in for the closing price of $25.90. PCRX’s price has ranged from $11.16 to $31.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 11.26% over the last five years. Meanwhile, its annual earnings per share averaged -9.41%. With a float of $44.25 million, this company’s outstanding shares have now reached $46.24 million.
The firm has a total of 790 workers. Let’s measure their productivity. In terms of profitability, gross margin is 71.6%, operating margin of -9.81%, and the pretax margin is -9.0%.
Pacira BioSciences Inc (PCRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Pacira BioSciences Inc is 4.38%, while institutional ownership is 111.41%. The most recent insider transaction that took place on Mar 06 ’25, was worth 11,625. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Medical Officer sold 879 for $18.40, making the entire transaction worth $16,174. This insider now owns 93,444 shares in total.
Pacira BioSciences Inc (PCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.47% during the next five years compared to -51.99% drop over the previous five years of trading.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Here are Pacira BioSciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.68. Likewise, its price to free cash flow for the trailing twelve months is 6.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.20, a number that is poised to hit 0.60 in the next quarter and is forecasted to reach 3.64 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Analysing the last 5-days average volume posted by the [Pacira BioSciences Inc, PCRX], we can find that recorded value of 0.63 million was lower than the volume posted last year of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 63.20%. Additionally, its Average True Range was 1.49.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 80.70%, which indicates a significant increase from 62.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.68% in the past 14 days, which was higher than the 54.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.60, while its 200-day Moving Average is $19.76. Now, the first resistance to watch is $26.14. This is followed by the second major resistance level at $26.83. The third major resistance level sits at $27.31. If the price goes on to break the first support level at $24.97, it is likely to go to the next support level at $24.49. Now, if the price goes above the second support level, the third support stands at $23.80.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
With a market capitalization of 1.18 billion, the company has a total of 46,276K Shares Outstanding. Currently, annual sales are 700,970 K while annual income is -99,560 K. The company’s previous quarter sales were 187,250 K while its latest quarter income was 16,040 K.
